Sponsor study identifier
interventional
1,161
0 countries
N/A
Study Start
June 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2007
Actual (reported)Study Completion
July 2007
Actual (reported)This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2006
Date type not reportedThis date has not been verified as actual or estimated.
June 30, 2006
Actual (reported)July 4, 2006
Actual (reported)July 2007
Actual (reported)July 2007
Actual (reported)August 13, 2009
Actual (reported)Clinical Resolution
Resolution of conjunctival discharge and bulbar conjunctival injection. (mITT, culture confirmed, as treated)
Day 5(+/- 1 day)
Microbial Eradication
eradication of baseline bacterial infection. modified intent to treat (mITT), culture confirmed, as treated
Day 5 (+/- 1 day)
Clinical Resolution
Day 8 or Day 9
Microbial Eradication
Day 8 or Day 9
Moxifloxacin hydrochloride ophthalmic solution 0.5%
Besifloxacin hydrochloride ophthalmic suspension 0.6%
Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
DeCory HH, Sanfilippo CM, Proskin HM, Blondeau JM. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. PLoS One. 2020 Aug 25;15(8):e0237603. doi: 10.1371/journal.pone.0237603. eCollection 2020.
Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675-85. doi: 10.2165/11536720-000000000-00000.
Timothy Comstock, OD
Bausch & Lomb Incorporated
1,161 participants (actual enrollment reported by the registry).
First Submitted
June 30, 2006
First Posted
July 4, 2006
Study Start
June 2006
Date type not reportedThis date has not been verified as actual or estimated.
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
Contact the study team to confirm eligibility.
Primary Completion
July 2007
Actual (reported)Study Completion
July 2007
Actual (reported)Last Updated
March 24, 2015
Results First Posted
August 13, 2009
Record last verified: 2015-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: